Klin Farmakol Farm. 2015;29(1):8-12

Overview of biological therapy for HER2-positive metastatic breast cancer

Tomáš Büchler, Jana Čejková
Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

Recognition of the importance of the HER2/neu receptor for the human epidermal growth factor has been a major progress in individualizing

the treatment in patients with breast cancer. HER2 is a key regulator of tumour cell apoptosis. Overexpression of HER2 enables

permanent activation of signalling pathways and acts as a factor stimulating tumour growth in breast cancer. Biological therapy that

blocks the HER2 receptor results in improved treatment outcomes. Available agents blocking the HER2 receptor include trastuzumab,

trastuzumab emtansine, lapatinib, and pertuzumab.

Keywords: breast cancer, HER2, targeted therapy, trastuzumab, trastuzumab emtansine, pertuzumab, lapatinib

Published: March 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Büchler T, Čejková J. Overview of biological therapy for HER2-positive metastatic breast cancer. Klin Farmakol Farm. 2015;29(1):8-12.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. ÚZIS. Novotvary 2013 ČR. www.uzis.cz.
    2. Jackisch C. HER-2-positive metastatic breast cancer: optimizin gtrastuzumab-based therapy. Oncologist 2006; 11(Suppl. 1): 34-41. Go to original source... Go to PubMed...
    3. Ryška A. Analýza dat z histologického registru Magister za období 2013. http://www.mojemedicina.cz/breast-cancer-news/analyza-dat-z-histologickeho-registru-magister-za-obdobi-2013/.
    4. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712. Go to original source...
    5. Klapper LN, Glathe S, Vaisman N, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may functions olely as a shared coreceptor for multiple stroma-derived growth factors. PNAS 1999; 96: 4995-5000. Go to original source...
    6. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51. Go to original source...
    7. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792. Go to original source...
    8. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: theM77001 study group. J Clin Oncol 2005; 23: 4265-4274. Go to original source... Go to PubMed...
    9. http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf.
    10. Verma S, Miles D, Gianni L, et al. Trastuzumabemtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791. Go to original source...
    11. Lipton A, Carney W, Martin A. Serum levels of HER2/neu extracellular domain (ECD) in clinical studies with lapatinib in HER2/neu-positive metastatic breast cancer (MBC). 2007 Breast Cancer Symposium. Abstract 105.
    12. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: update defficacy and biomarker analyses. Breast Cancer Res Treat. 2008 Jan 11. (Epub ahead of print). Go to original source... Go to PubMed...
    13. O'Shaughnessy J, Blackwell KL, Burstein H. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008; 26(May 20 suppl): Abstract 1015. Go to original source... Go to PubMed...
    14. Cortés J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab - based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30: 1594-600. Go to original source...
    15. http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002547/WC500140980.pdf.
    16. Breast cancer. NCCN Clinical Practice Guidelines in Oncology. Version 3.2014. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
    17. Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014; 32(19): 2078-2099. Go to original source... Go to PubMed...
    18. Brufsky AM. Current approaches and emerging directions in her2-resistant breast cancer. Breast Cancer (Auckl). 2014; 8: 109-118. Go to original source...
    19. Státní ústav pro kontrolu léčiv. Databáze léků. http://www.sukl.cz/modules/medication/search.php.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.